. 2022 Oct 3;12(10):e060606. doi: 10.1136/bmjopen-2021-060606

Table 4.

Estimated continuation rates at 12 months of IUD types from the included studies

IUD type	Continuation rates with numbers of patients (n) and statistical heterogeneity (tau² and I²) values of studies included in subgroup
IUD type	Nulliparous women aged <30	Nulliparous women of any age	Overall effect size (all studies)
TCu 380A*	81.60% (95% CI 76.52% to 86.21%)† (n=264; tau²=0.0; I²=0.0%, p=0.69)^{19 34}	80.97% (95% CI 76.04% to 85.48%) (n=971; tau²=0.005; I²=27.6%, p=0.25)^{19 30 45}	81.93% (95% CI 79.66% to 84.09%) (n=1235; tau²=0.0; I²=0.0%, p=0.62)19 30 34 45
Smaller TCu 380A‡	Not applicable—only one study group	91.02% (95% CI 88.01% to 93.64%) (n=420; tau²=0.0; I²=0.0%, p=0.51)^{30 44}	91.02% (95% CI 88.01% to 93.64%) (n=420; tau²=0.0; I²=0.0%, p=0.51)^{30 44}
TCu 300	Not applicable—no study	81.92% (95% CI 78.35% to 85.24%) (n=485; tau²=0.0; I²=17.3%, p=0.27)^{45 47}	81.92% (95% CI 78.35% to 85.24%) (n=485; tau²=0.0; I²=17.3%, p=0.27)^{45 47}
TCu 200	73.03% (95% CI 67.63% to 78.10%) (n=5111; tau²=0.010; I²=94.2%, p=<0.01)³⁷	76.51% (95% CI 72.67% to 80.14%) (n=3277; tau²=0.012; I²=84.0%, p=<0.01)37–39 41 43 45	75.44% (95% CI 72.32% to 78.43%) (n=8388; tau²=0.012; I²=89.9%, p=<0.01)37–39 41 43 45
Nova T200	Not applicable—no study	73.21% (95% CI 70.10% to 76.22%) (n=818; tau²=0.0; I²=0.0%, p=0.94)^{39 40}	73.21% (95% CI 70.10% to 76.22%) (n=818; tau²=0.0; I²=0.0%, p=0.94)^{39 40}

*Excludes Otero-Flores et al’s study data.

†Includes women aged 30 from Hall and Kutler’s study data.

‡TCu 380A Nul/Mini TT380 Slimline IUDs.

IUD, intrauterine device.